Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 14 of 14 publications.

Pandya AG, Amoloja T, Bibeau K, DiBenedetti D, Kosa K, Butler K, Kornacki D, Ezzedine K. Assessing participants' experiences with vitiligo from patient interviews. Dermatol Ther. 2024 Sep;14(9):2467-78. doi: 10.1007/s13555-024-01241-w

Armstrong AW, Jayade S, Rege S, Joshi N, Patel V, Kalirai S, Wolin D, Boyle K, Patel D, Seigel L. Evaluating treatment choice in patients with moderate to severe psoriasis in the United States: results from a US patient survey. Dermatol Ther. 2024 Feb;14(2):421-39. doi: 10.1007/s13555-023-01089-6

Simon TA, Suissa S, Skovron ML, Frisell T, Askling J, Michaud K, Pedro S, Strangfeld A, Meissner Y, Boers M, Hoffman V, Dominique A, Gomez A, Hochberg MC. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study. Semin Arthritis Rheum. 2024 Feb;64:152313. doi: 10.1016/j.semarthrit.2023.152313

Chebib FT, Zhou X, Garbinsky D, Davenport E, Nunna S, Oberdhan D, Fernandes A. Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational studies. Kidney Med. 2023 Jun;5(6):100639. doi: 10.1016/j.xkme.2023.100639

Paller AS, Yosipovitch G, Weidinger S, DiBenedetti D, Whalley D, Gadkari A, Guillemin I, Zhang H, Eckert L, Chao J, Bansal A, Chuang CC, Delevry D. Development, psychometric validation and responder definition of worst itch scale in children with severe atopic dermatitis. Dermatol Ther. 2022 Dec;12(12):2839-50. doi: 10.1007/s13555-022-00804-z

Wyrwich KW, Winnette R, Bender R, Gandhi K, Williams N, Harris N, Nelson L. Validation of the alopecia areata patient priority outcomes (AAPPO) questionnaire in adults and adolescents with alopecia areata. Dermatol Ther. 2022 Jan;12(1):149-66. doi: 10.1007/s13555-021-00648-z

Sulyok CJ, Fox L, Ritchie H, Lanzas C, Lenhart S, Day J. Mathematically modeling the effect of touch frequency on the environmental transmission of Clostridioides difficile in healthcare settings. Math Biosci. 2021 Oct;340:108666. doi: 10.1016/j.mbs.2021.108666

Houghton K, Patil D, Gomez B, Feldman SR. Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase 3 clinical trials of Secukinumab. Dermatol Ther. 2021 Aug;11(4):1373-84. doi: 10.1007/s13555-021-00564-2

Simpson EL, de Bruin-Weller M, Bansal A, Chen Z, Nelson L, Whalley D, Prescilla R, Guillemin I, Delevry D. Definition of clinically meaningful within-patient changes in POEM and CDLQI in children 6 to 11 years of age with severe atopic dermatitis. Dermatol Ther. 2021 Aug;11(4):1415-22. doi: 10.1007/s13555-021-00543-7

Winnette R, Martin S, Harris N, Deal LS. Development of the alopecia areata patient priority outcomes instrument: a qualitative study. Dermatol Ther. 2021 Apr;11(2):599-613. doi: 10.1007/s13555-021-00508-w

Simpson EL, de Bruin-Weller M, Eckert L, Whalley D, Guillemin I, Reaney M, Chen Z, Nelson L, Qin S, Bansal A, Gadkari A. Responder threshold for Patient-Oriented Eczema Measure (POEM) and Children's Dermatology Life Quality Index (CDLQI) in adolescents with atopic dermatitis. Dermatol Ther. 2019 Dec;9(4):799-805. doi: 10.1007/s13555-019-00333-2

Kuznik A, Bego-Le-Bagousse G, Eckert L, Gadkari A, Simpson E, Graham CN, Miles L, Mastey V, Mahajan P, Sullivan SD. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther. 2017 Dec;7(4):493-505. doi: 10.1007/s13555-017-0201-6

Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Does switching anti-TNFα biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach. Semin Arthritis Rheum. 2014 Aug;44(1):39-46. doi: 10.1016/j.semarthrit.2014.03.001

Thyagarajan (Hoffman) V, Norman H, Alexander KA, Napalkov P, Enger C. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients. Semin Arthritis Rheum. 2012 Dec;42(3):223-33. doi: 10.1016/j.semarthrit.2012.05.004